US 11,690,828 B2
Treatment of CNS diseases with sGC stimulators
Joon Jung, Newton, MA (US); Thomas Wai-Ho Lee, Lexington, MA (US); Rajesh R. Iyengar, West Newton, MA (US); Nicholas Robert Perl, Somerville, MA (US); Peter Germano, Newton, MA (US); Maria D. Ribadeneira, Cambridge, MA (US); and Kim Tang, Belmont, MA (US)
Assigned to Cyclerion Therapeutics, Inc., Cambridge, MA (US)
Appl. No. 16/348,359
Filed by Cyclerion Therapeutics, Inc., Cambridge, MA (US)
PCT Filed Nov. 7, 2017, PCT No. PCT/US2017/060299
§ 371(c)(1), (2) Date May 8, 2019,
PCT Pub. No. WO2018/089328, PCT Pub. Date May 17, 2018.
Claims priority of provisional application 62/419,059, filed on Nov. 8, 2016.
Prior Publication US 2019/0343813 A1, Nov. 14, 2019
Int. Cl. A61K 31/437 (2006.01); A61K 31/506 (2006.01); A61P 25/28 (2006.01); A61K 31/5025 (2006.01); A61K 31/519 (2006.01)
CPC A61K 31/437 (2013.01) [A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61K 31/519 (2013.01); A61P 25/28 (2018.01)] 2 Claims
 
1. A method of enhancing memory or reversing memory disruption or impairment in a subject in need thereof, comprising administering, alone or in combination therapy, a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof to the subject in need thereof, wherein the compound is selected from those depicted in Table I, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or a dosage form comprising said compound or pharmaceutically acceptable salt thereof:
 
 TABLE I
 
 
 
 
 Compound
 
 Structure Number
 
 
 
 

OG Complex Work Unit Chemistry
 I-5
 
 
 
 

OG Complex Work Unit Chemistry
  I-2.